Improved Effectiveness from Individualized Dosing of Self-Administered Biologics for the Treatment of Moderate-to-Severe Psoriasis: A 5-Year Retrospective Chart Review from a Spanish University Hospital.

CONCLUSION: Ustekinumab was the safest and most efficient treatment. Etanercept showed the highest treatment failure rate, incurring higher costs. Dosage individualization according to patient needs improves the therapy efficiency, reducing therapeutic failure and derived costs. PMID: 30924390 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30924390?dopt=Abstract

Source: Journal of Dermatological Treatment - March 31, 2019 Category: Dermatology Tags: J Dermatolog Treat Source Type: research